Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adial Pharmaceuticals (ADIL) Cash from Financing Activities (2022 - 2024)

Adial Pharmaceuticals' Cash from Financing Activities history spans 3 years, with the latest figure at $3.6 million for Q3 2024.

  • For Q3 2024, Cash from Financing Activities rose 2503.61% year-over-year to $3.6 million; the TTM value through Dec 2024 reached $7.8 million, up 89.87%, while the annual FY2025 figure was $8.5 million, 8.0% up from the prior year.
  • Cash from Financing Activities for Q3 2024 was $3.6 million at Adial Pharmaceuticals, up from $411091.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $9.1 million in Q1 2022 and bottomed at $58.0 in Q2 2023.
  • The 3-year median for Cash from Financing Activities is $609613.0 (2023), against an average of $2.3 million.
  • The largest annual shift saw Cash from Financing Activities tumbled 96.89% in 2023 before it surged 708677.59% in 2024.
  • A 3-year view of Cash from Financing Activities shows it stood at $1865.0 in 2022, then soared by 181334.69% to $3.4 million in 2023, then increased by 6.7% to $3.6 million in 2024.
  • Per Business Quant, the three most recent readings for ADIL's Cash from Financing Activities are $3.6 million (Q3 2024), $411091.0 (Q2 2024), and $3.8 million (Q1 2024).